Thorax:生命早期生活贫困,青少年持续性哮喘风险增加70%

2021-12-13 小文子 MedSci原创

围产期特征和生命早期家庭环境在解释英国青少年持续性哮喘的社会经济不平等方面,比家庭外环境暴露更为重要。

在英国,围产期和生命早期环境特征作为早期社会经济环境(SECs)因素对青少年持续性哮喘中介效应的相对重要性尚不清楚。Thorax杂志的一项研究使用因果中介效应分析英国青少年持续性哮喘社会不平等相关的生命早年风险因素的相对重要性。

纳入英国千禧队列研究(Millennium Cohort Study, MCS)中7487例儿童和青少年,对相关数据进行因果中介效应分析。持续性哮喘定义为在7岁、11岁或14岁的任意两个或以上时间点诊断哮喘。主要影响因素是母亲教育,这是衡量生命早期社会经济环境(SECs)的方法,用于计算不平等的相对指数。研究人员评估了围产期(9个月时测量产妇健康行为、婴儿特征和母乳喂养持续时间)和环境风险因素(3年使测量家庭住房条件;儿童保育类型和兄弟姐妹数量可能的潜在感染暴露及邻里特征)介导的儿童期SECs对持续性哮喘风险的总效应,计算每种介质的自然直接效应(NDE)、自然间接效应(NIE)、总效应(TE)和介导比例。

结果显示,14岁儿童持续性哮喘的总患病率为15.2%。学历较低母亲所生孩子14岁时持续性哮喘的风险更高,具有明显的社会梯度(本科学历以上:12.8%;无学历:20.3%)。NDE(OR=1.27; 95%, 0.62-2.63)增加了持续性哮喘的可能性;NIE仅通过介质对SEC发挥效应,当SEC在最高水平时,持续性哮喘发生率增加31%,介质水平自然发生在最低SEC与最高SEC(NIE OR=1.31; 95%CI, 1.04-1.65)之间。围产期特征介导占37.5%(95%CI, 30.6-43.3),住房条件介导占61.2%(56.0-65.4)。总体而言,SEC对青少年持续性哮喘风险的总效应(OR=1.70; 95%CI 1.20-2.40)的58.9%(95%CI 52.9-63.7)是由围产期和环境特征介导的。

结果表明,围产期特征和生命早期家庭环境在解释英国青少年持续性哮喘的社会经济不平等方面,比家庭外环境暴露更为重要。

原文出处:

Hanna Creese, Eric Lai, et al, Disadvantage in early- life and persistent asthma in adolescents: a UK cohort study, Thorax, doi:10.1136/thoraxjnl-2021-217312.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1740581, encodeId=8e3c1e405814c, content=<a href='/topic/show?id=ffdc9242430' target=_blank style='color:#2F92EE;'>#贫困#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=92424, encryptionId=ffdc9242430, topicName=贫困)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=192134785590, createdName=654699882_84926997, createdTime=Sat Oct 15 15:38:36 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023089, encodeId=f4eb20230895e, content=<a href='/topic/show?id=d70839954ab' target=_blank style='color:#2F92EE;'>#哮喘风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39954, encryptionId=d70839954ab, topicName=哮喘风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 20 02:38:36 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922634, encodeId=dcab192263422, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Thu Jul 28 01:38:36 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081163, encodeId=9e12108116319, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed292957767, createdName=黄婷婷, createdTime=Fri Dec 17 14:26:23 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079649, encodeId=6c2110e9649d2, content=发展模式识别器, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210821/285a12750b6f479abbc2cb84dfb7885e/1073447e075b4528b9a08483aefe5172.jpg, createdBy=79975576266, createdName=今天明天aaaaaaf9, createdTime=Mon Dec 13 19:01:24 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1740581, encodeId=8e3c1e405814c, content=<a href='/topic/show?id=ffdc9242430' target=_blank style='color:#2F92EE;'>#贫困#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=92424, encryptionId=ffdc9242430, topicName=贫困)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=192134785590, createdName=654699882_84926997, createdTime=Sat Oct 15 15:38:36 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023089, encodeId=f4eb20230895e, content=<a href='/topic/show?id=d70839954ab' target=_blank style='color:#2F92EE;'>#哮喘风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39954, encryptionId=d70839954ab, topicName=哮喘风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 20 02:38:36 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922634, encodeId=dcab192263422, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Thu Jul 28 01:38:36 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081163, encodeId=9e12108116319, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed292957767, createdName=黄婷婷, createdTime=Fri Dec 17 14:26:23 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079649, encodeId=6c2110e9649d2, content=发展模式识别器, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210821/285a12750b6f479abbc2cb84dfb7885e/1073447e075b4528b9a08483aefe5172.jpg, createdBy=79975576266, createdName=今天明天aaaaaaf9, createdTime=Mon Dec 13 19:01:24 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1740581, encodeId=8e3c1e405814c, content=<a href='/topic/show?id=ffdc9242430' target=_blank style='color:#2F92EE;'>#贫困#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=92424, encryptionId=ffdc9242430, topicName=贫困)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=192134785590, createdName=654699882_84926997, createdTime=Sat Oct 15 15:38:36 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023089, encodeId=f4eb20230895e, content=<a href='/topic/show?id=d70839954ab' target=_blank style='color:#2F92EE;'>#哮喘风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39954, encryptionId=d70839954ab, topicName=哮喘风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 20 02:38:36 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922634, encodeId=dcab192263422, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Thu Jul 28 01:38:36 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081163, encodeId=9e12108116319, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed292957767, createdName=黄婷婷, createdTime=Fri Dec 17 14:26:23 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079649, encodeId=6c2110e9649d2, content=发展模式识别器, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210821/285a12750b6f479abbc2cb84dfb7885e/1073447e075b4528b9a08483aefe5172.jpg, createdBy=79975576266, createdName=今天明天aaaaaaf9, createdTime=Mon Dec 13 19:01:24 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1740581, encodeId=8e3c1e405814c, content=<a href='/topic/show?id=ffdc9242430' target=_blank style='color:#2F92EE;'>#贫困#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=92424, encryptionId=ffdc9242430, topicName=贫困)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=192134785590, createdName=654699882_84926997, createdTime=Sat Oct 15 15:38:36 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023089, encodeId=f4eb20230895e, content=<a href='/topic/show?id=d70839954ab' target=_blank style='color:#2F92EE;'>#哮喘风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39954, encryptionId=d70839954ab, topicName=哮喘风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 20 02:38:36 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922634, encodeId=dcab192263422, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Thu Jul 28 01:38:36 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081163, encodeId=9e12108116319, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed292957767, createdName=黄婷婷, createdTime=Fri Dec 17 14:26:23 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079649, encodeId=6c2110e9649d2, content=发展模式识别器, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210821/285a12750b6f479abbc2cb84dfb7885e/1073447e075b4528b9a08483aefe5172.jpg, createdBy=79975576266, createdName=今天明天aaaaaaf9, createdTime=Mon Dec 13 19:01:24 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
    2021-12-17 黄婷婷

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1740581, encodeId=8e3c1e405814c, content=<a href='/topic/show?id=ffdc9242430' target=_blank style='color:#2F92EE;'>#贫困#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=92424, encryptionId=ffdc9242430, topicName=贫困)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=192134785590, createdName=654699882_84926997, createdTime=Sat Oct 15 15:38:36 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023089, encodeId=f4eb20230895e, content=<a href='/topic/show?id=d70839954ab' target=_blank style='color:#2F92EE;'>#哮喘风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39954, encryptionId=d70839954ab, topicName=哮喘风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 20 02:38:36 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922634, encodeId=dcab192263422, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Thu Jul 28 01:38:36 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081163, encodeId=9e12108116319, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed292957767, createdName=黄婷婷, createdTime=Fri Dec 17 14:26:23 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079649, encodeId=6c2110e9649d2, content=发展模式识别器, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210821/285a12750b6f479abbc2cb84dfb7885e/1073447e075b4528b9a08483aefe5172.jpg, createdBy=79975576266, createdName=今天明天aaaaaaf9, createdTime=Mon Dec 13 19:01:24 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
    2021-12-13 今天明天aaaaaaf9

    发展模式识别器

    0

相关资讯

Lancet Respir Med :苏格兰5~17岁哮喘儿童COVID-19住院风险

近期住院或接受2个或以上疗程口服糖皮质激素治疗的学龄期哮喘儿童住院风险显著增加。

J Allergy Clin Immunol Pract:过敏性鼻炎和哮喘对COVID-19感染、住院和死亡率的影响

调查了AR和/或哮喘在COVID-19感染、严重程度和死亡率中的影响,并评估了长期服用AR和/或哮喘药物是否影响COVID-19的结果。

AJRCCM:哮喘表型与新冠肺炎的风险

严重哮喘与重症新冠肺炎结局相关。

CRTH2拮抗剂对鼻病毒感染引起哮喘急性加重的影响

timapiprant是否能降低或预防实验性鼻病毒(RV)诱导的哮喘急性加重?

被黑框警告的孟鲁司特钠,该如何安全使用?

在2020年3月,美国食品药品监督管理局(FDA)发布了一则药品安全信息警告,针对处方药孟鲁司特纳可能出现的严重精神健康副作用(风险可能包括产生自杀的想法或行为),发出黑框警告

欧洲发布5-16岁儿童哮喘诊断临床实践指南

工作组建议将肺活量测定、支气管舒张试验和FeNO作为儿童哮喘的一线诊断试验。